Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsHoward Feldman, MD, FRCPC, FAAN (Neurology)
Professor AdjunctAbout
Copy Link
Research
Copy Link
Overview
Medical Research Interests
Dementia; Information Science; Named Groups
Research at a Glance
Yale Co-Authors
Frequent collaborators of Howard Feldman's published research.
Publications Timeline
A big-picture view of Howard Feldman's research output by year.
Research Interests
Research topics Howard Feldman is interested in exploring.
James Brewer
Godfrey Pearlson, MA, MBBS
Harlan Krumholz, MD, SM
281Publications
13,551Citations
Publications
2026
A Randomized Controlled Trial of Prazosin for Disruptive Agitation in Alzheimer’s Disease: PEACE-AD
Peskind E, Raskind M, Herman M, Morrison R, Matthews G, Evans A, Boyarko B, Peavy G, Léger G, Jicha G, Patel N, Brangman S, Pierce A, Schneider L, Jin S, Zhang J, Thomas R, Messer K, Cho H, Feldman H, Study A. A Randomized Controlled Trial of Prazosin for Disruptive Agitation in Alzheimer’s Disease: PEACE-AD. The American Journal Of Geriatric Psychiatry Open Science Education And Practice 2026, 11: 15-27. DOI: 10.1016/j.osep.2026.05.001.Peer-Reviewed Original ResearchAltmetricEstimating treatment effects in clinical studies of Alzheimer's disease: What are estimands and why do we need them?
Hendrix S, Mallinckrodt C, Abschneider R, Atri A, Bendtsen M, Colombo T, Feldman H, Johannsen P, Cummings J. Estimating treatment effects in clinical studies of Alzheimer's disease: What are estimands and why do we need them? Alzheimer's & Dementia 2026, 22: e71676. PMID: 42644414, PMCID: PMC13508584, DOI: 10.1002/alz.71676.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAltmetricNeurodevelopmental and Neurobehavioral Outcomes of Prematurity
Hosoki M, Loe I, Feldman H. Neurodevelopmental and Neurobehavioral Outcomes of Prematurity. 2026, 588-598. DOI: 10.1017/9781009418034.041.BooksSafety considerations of gene‐based therapies for Alzheimer's disease
Bevins E, Léger G, Herman M, Ringman J, Roy S, Shtrahman M, Pa J, Feldman H. Safety considerations of gene‐based therapies for Alzheimer's disease. Alzheimer's & Dementia 2026, 22: e71515. PMID: 42427159, PMCID: PMC13351316, DOI: 10.1002/alz.71515.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAltmetricNeonatal brain-age models in full- and preterm infants
Chiu H, Richie-Halford A, Lazarus M, Rokem A, Poblaciones R, Marchman V, Travis K, Scala M, Feldman H, Yeatman J. Neonatal brain-age models in full- and preterm infants. Developmental Cognitive Neuroscience 2026, 80: 101775. PMID: 42400972, PMCID: PMC13355775, DOI: 10.1016/j.dcn.2026.101775.Peer-Reviewed Original ResearchAltmetricAutism screening and diagnosis in children with congenital heart disease
Perez N, Rios P, Marchman V, Aishworiya R, Wang S, Feldman H. Autism screening and diagnosis in children with congenital heart disease. Frontiers In Pediatrics 2026, 14: 1839114. PMID: 42382645, PMCID: PMC13314728, DOI: 10.3389/fped.2026.1839114.Peer-Reviewed Original ResearchCitationsAltmetric“We feel like we don’t matter”: the work experience of caring for long-term care residents with suspected trauma-related responsive behaviors
Minion J, Huijer H, Akintunde T, Hegadoren K, Feldman H, Lanius R, Banerjee S, Ginsburg L, Silvius J, Little L, Norton P, Estabrooks C. “We feel like we don’t matter”: the work experience of caring for long-term care residents with suspected trauma-related responsive behaviors. BMC Health Services Research 2026, 26: 1051. PMID: 42218489, PMCID: PMC13430844, DOI: 10.1186/s12913-026-14785-8.Peer-Reviewed Original ResearchAltmetricPlain language summary: the evoke(+) studies of semaglutide for early Alzheimer’s disease
Cummings J, Atri A, Sano M, Zetterberg H, Scheltens P, Knop F, Johannsen P, Wichmann C, Abschneider R, Leon T, Taylor J, Feldman H. Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer’s disease. Neurodegenerative Disease Management 2026, 16: 381-390. PMID: 42159155, PMCID: PMC13390525, DOI: 10.1080/17582024.2026.2666332.Peer-Reviewed Original ResearchAltmetricEfficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials
Cummings J, Atri A, Sano M, Zetterberg H, Scheltens P, Knop F, Johannsen P, Wichmann C, Abschneider R, Leon T, Feldman H. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet 2026, 407: 2167-2179. PMID: 41865758, DOI: 10.1016/s0140-6736(26)00459-9.Peer-Reviewed Original ResearchCitationsAltmetricAlternative approaches to improving language outcomes in young children
Feldman H, Marchman V. Alternative approaches to improving language outcomes in young children. PEDIATRICS 2026, 157: e2025075539. PMID: 41833319, PMCID: PMC13552639, DOI: 10.1542/peds.2025-075539.Peer-Reviewed Original ResearchAltmetric
Get In Touch
Copy Link